Show
Sort by
-
- Journal Article
- A1
- open access
Upadacitinib in active ankylosing spondylitis : results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension
-
- Journal Article
- A1
- open access
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors : a consensus statement
-
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1) : a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial
-
Clinical and quality of life improvements with golimumab or infliximab in a real-life ankylosing spondylitis population : the QUO-VADIS study
-
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis
-
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis
-
Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations
-
Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS
-
Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study
-
Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort